Kejun Nan

Kejun Nan


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Cancer Letters
Verified
Journal Article
Closed access
THTing-Hua Hu
Ting-Hua Hu
YYYu Yao
Yu Yao
SYShuo Yu
Shuo Yu
LHLi-Li Han
Li-Li Han
WWWen-Juan Wang
Wen-Juan Wang
KNKejun Nan
Kejun Nan

11 June 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MWMin-Cong Wang
Min-Cong Wang
CLChun-Li Li
Chun-Li Li
JCJie Cui
Jie Cui
MJMin Jiao
Min Jiao
TWTao Wu
Tao Wu
KNKejun Nan
Kejun Nan
BMI-1 oncogene is a member of the polycomb-group gene family and a transcriptional repressor. Overexpression of BMI-1 has been identified in various human cancer tissues and is known to be involved in cancer cell proliferation, cell invasion, distant metastasis, chemosensitivity and patient survival. Accumulating evidence has revealed that BMI-1 is also involved in the regulation of self-renewal, differentiation and tumor initiation of cancer stem cells (CSCs). However, the molecular mechanisms underlying these biological processes remain unclear. The present review summarized the function of BMI-1 in different human cancer types and CSCs, and discussed the signaling pathways in which BMI-1 is potentially involved. In conclusion, BMI-1 may represent a promising target for the prevention and therapy of various cancer types.

1 December 2015 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
TWTao Wu
Tao Wu
XLXuan Liang
Xuan Liang
MWMin-Cong Wang
Min-Cong Wang
LJLi Jing
Li Jing
ZLZhi-Yan Liu
Zhi-Yan Liu
KNKejun Nan
Kejun Nan
Resistance to cisplatin-based therapy is a major challenge in the control of lung cancer progression. However, the underlying mechanisms remain largely unclear. Autophagy is closely associated with resistance to lung cancer therapy, but the function of autophagy in cisplatin treatment is still controversial. Here, we investigated whether autophagy was involved in lung adenocarcinoma resistance to cisplatin and further elucidated the underlying molecular mechanisms. Cisplatin-refractory lung adenocarcinoma cells increased autophagic vacuole formation detected by monodansylcadaverine staining. When exposed to cisplatin, lung adenocarcinoma cells demonstrated increased levels of autophagy detected by MAP1A/1B LC3B and mammalian homologue of yeast Atg6 (Beclin-1) expression using Western blot analysis. Activation of cisplatin-induced autophagic flux was increased by using chloroquine (CQ), which can accumulate LC3B-II protein and increase punctate distribution of LC3B localization. The combination of cisplatin with CQ was more potent than cisplatin alone in inhibiting lung adenocarcinoma cell growth, which also increased cisplatin-induced apoptosis. Compared to cisplatin treatment alone, the combination of cisplatin and CQ decreased p-AMPK and increased p-mTOR protein expressions, in addition, the AMPK inhibitor Compound C plus cisplatin downregulated p-AMPK and upregulated p-mTOR as well as depressed LC3B cleavage. These findings demonstrate that activation of autophagy is a hallmark of cisplatin exposure in human lung adenocarcinoma cells, and that there is a cisplatin-induced autophagic response via activation of the AMPK/mTOR signaling pathway. We speculate that autophagy can be used as a novel therapeutic target to overcome cisplatin-resistant lung adenocarcinoma.

29 April 2010 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
TTTao Tian
Tao Tian
KNKejun Nan
Kejun Nan
SWShu-Hong Wang
Shu-Hong Wang
XLXuan Liang
Xuan Liang
CLChuang-Xin Lu
Chuang-Xin Lu
ZRZhi-Ping Ruan
Zhi-Ping Ruan
Hepatocellular carcinoma (HCC) is a typical hypervascular tumor, and increased levels of vascular endothelial growth factor (VEGF) are associated with progression of HCC. Tumor suppression gene PTEN (phosphatase and tensin homolog deleted on chromosome 10), an important antagonist of the phosphoinositide-3-kinase (PI3K)/adenosine triphosphate-dependent tyrosine kinase (Akt) pathway, is also commonly lost or mutated in HCC. However, the effect of PTEN on VEGF-mediated angiogenesis in HCC remains unknown. To explore this relationship, we expressed a panel of PTEN mutants in human HCC cells with low expression of PTEN (HepG2 cells). Overexpression of PTEN in HepG2 cells resulted in the downregulation of proliferation and migration of cocultured endothelial cells and decreased expression of hypoxia-inducible factor 1 (HIF-1) and VEGF. Similarly, using a nude mouse model, we demonstrated that PTEN decreased expression of HIF-1 and VEGF and suppressed HepG2-induced angiogenesis. This inhibitory effect was not observed in cells expressing a phosphatase-deficient PTEN mutant, suggesting that PTEN inhibits angiogenesis and VEGF through a phosphatase-dependent pathway. Strikingly, reintroducing the C2 domain of PTEN also resulted in a significant decrease in angiogenesis and VEGF expression, although it did not affect Akt phosphorylation or HIF-1 expression. In summary, this study suggests the novel viewpoint that PTEN suppresses angiogenesis and VEGF expression in HCC through both phosphatase-dependent and -independent mechanisms.

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LHLi-Li Han
Li-Li Han
YLYi Lv
Yi Lv
HGHui Guo
Hui Guo
ZRZhi-Ping Ruan
Zhi-Ping Ruan
KNKejun Nan
Kejun Nan
Hepatocellular carcinoma (HCC) is one of the most frequent tumors worldwide and accounts for approximately one-third of all malignancies. In the past decade, advances have been made to improve the prognosis of HCC, including improvement in the clinical diagnosis of early-stage HCC using molecular biomarkers and molecular-targeted therapy to treat advanced HCC. However, the diagnosis, pathogenesis and targeted therapy of HCC are not completely independent, and should be comprehensively studied. For example, a number of tumor markers provide useful clinical information not only for prognosis, but also in pathogenesis and treatment efficacy. Therefore, this review will focus on the role of several specific biomarkers implicated in the pathogenesis of HCC and several promising molecular-targeted drugs that target the biomarkers of HCC.

1 December 2017 in Cancer Letters
Verified
Journal Article
Closed access
SYsizhe yu
sizhe yu
YWYu Wang
Yu Wang
LJLi Jing
Li Jing
FCFrancois-xavier Claret
Francois-xavier Claret
QLQing Li
Qing Li
HGHui Guo
Hui Guo